As previously communicated, Anders Essen-Möller has committed to subscribe for units corresponding to SEK 5 million. Furthermore, CEO Ulf Hannelius and CFO Anna Styrud have committed to subscribe for their respective pro rata share of the Rights Issue, corresponding to approximately SEK 0.7 million and SEK 0.3 million. Vice Chairman of the Board of Directors, Erik Nerpin, has committed to subscribe for units corresponding to SEK 0.1 million.

In total, the Rights Issue is thus covered by subscription commitments and subscription intentions equivalent to approximately SEK 17.5 million, corresponding to approximately 8.4 percent of the Rights Issue.

The subscription period for Diamyd Medical's rights issue runs from April 15 through April 29, 2025.

As previously announced, the U.S. Food and Drug Administration (FDA) has confirmed that Diamyd Medical's ongoing Phase 3 trial, DIAGNODE-3, meets the requirements for accelerated approval. The trial has thus received clearance for an earlier readout already in March 2026.

Prospectus
An EU growth prospectus with complete terms and conditions for the Rights Issue will be published and made available before the subscription period commences on Diamyd Medical's website, www.diamyd.com, and on Aqurat Fondkommission AB's website, www.aqurat.se.

Advisors
G&W Fondkommission acts as Financial Advisor to Diamyd Medical in connection with the Rights Issue. Aqurat Fondkommission AB has been appointed as Issuer Agent.

About Diamyd Medical
Diamyd Medical develops precision medicine therapies to prevent and treat Type 1 Diabetes and LADA (Latent Autoimmune Diabetes in Adults). Diamyd^® is an investigational antigen-specific immunomodulatory therapeutic for the preservation of endogenous insulin production specifically for individuals carrying a HLA DR3-DQ2 gene. Diamyd^® has been granted Orphan Drug Designation in the U.S. as well as Fast Track Designation by the U.S. FDA for the treatment of Stage 3 (clinically diagnosed symptomatic) Type 1 Diabetes. Diamyd^® has also been granted Fast Track Designation for the treatment of Stage 1 and 2 (pre-symptomatic) Type 1 Diabetes. DIAGNODE-3, a confirmatory Phase III trial is actively recruiting patients with recent-onset (Stage 3) Type 1 Diabetes at 60 clinics in eight European countries and in the US. Significant results have previously been shown in a large genetically predefined patient group - in a large-scale meta-analysis as well as in the Company's prospective European Phase IIb trial, where Diamyd^® was administered directly into a superficial lymph node in children and young adults with recently diagnosed Type 1 Diabetes. The DIAGNODE-3 trial is recruiting only this patient group that carries the common genotype known as HLA DR3-DQ2, which constitutes approximately 40 % of patients with Type 1 Diabetes in Europe and the US. Injections into a superficial lymph node can be performed in minutes and are intended to optimize the treatment response. A biomanufacturing facility is under development in Umeå, Sweden, for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd^®. Diamyd Medical is a major shareholder in the stem cell company NextCell Pharma AB and in the artificial intelligence company MainlyAI AB.

Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.